Sugi Predict

Sugi Predict / Compounds / SCHEMBL2233260

SCHEMBL2233260

SCHEMBL2233260

Cc1cc(C)nc(N(C)CCCN(C)c2ccc(NC(=O)C(=O)c3c(-c4ccccc4)c(C)c4ccccn34)cc2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 6/20 0.34
▸ MAPT P10636 6/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ KMT2A Q03164 4/20 0.34
▸ PPARG P37231 3/20 0.34
▸ NCOR2 Q9Y618 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ NR2E3 Q9Y5X4 2/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ GPR55 Q9Y2T6 1/20 0.34
▸ MCHR1 Q99705 4/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646517 0.97 LMNA (0.36) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL1645527 0.93 PPARG (0.36) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL1645910 0.90 LMNA (0.36) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL1645861 0.88 ALDH1A1 (0.35) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL1646893 0.87 LMNA (0.35) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL2230968 0.85 SMN1; SMN2 (0.51) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL1993613 0.82 LMNA (0.37) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL2231616 0.81 SMN1; SMN2 (0.53) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL1646524 0.81 LMNA (0.43) LMNASMN1; SMN2HTTUSP2ALDH1A1
SCHEMBL2231005 0.80 LMNA (0.43) LMNASMN1; SMN2HTTUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 — — EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 LMNA 3870/4885SMN1; SMN2 3682/4885HTT 1809/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 LMNA 1805/4885SMN1; SMN2 3079/4885HTT 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.